ArrePath
Princeton, United States · Data And Analytics, Information Technology, Science And Engineering · 9 employees
ArrePath is a biotech company discovering and developing new and differentiated classes of anti-infectives to address antimicrobial resistance (AMR) through the application of state of the art technologies and novel strategies. We apply world-class science and innovation in imaging and AI / ML technologies to identify and develop novel drugs to address global health issues. Our advanced mach
Funding history
- Series seed — $1.0M — Nov 2024
Recent signals
- Nov 19, 2024: Kevin Krause appointed as President and Chief Executive Officer of ArrePath, Inc.
- Nov 19, 2024: Raised $1.0M in Series seed
See plans & pricing → Track ArrePath’s funding, hiring, and signals — with verified contacts — on Fundz.